COMBIPRES
LOE ApproachingNDAORALTABLETPriority Review
Approved
Sep 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMBIPRES is an oral tablet small-molecule NDA approved in 1974 by Boehringer Ingelheim. The product is a fixed-dose combination indicated for hypertension management. The specific indications and mechanism of action are not detailed in available data.
LOE Approaching
Product is in late-stage lifecycle with approaching loss of exclusivity, suggesting a smaller, maintenance-focused team rather than growth-oriented roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job postings and approaching LOE, COMBIPRES offers limited career growth opportunities. Roles on this product are typically smaller teams managing legacy brands focused on cost containment, regulatory maintenance, and post-LOE strategy rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on COMBIPRES at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.